A Phase 3 interventional study of Ritlecitinib and Placebo in Stable Nonsegmental Vitiligo and Active Nonsegmental Vitiligo, sponsored by Pfizer. Completed at 115 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.
Among the 80 studies in Vitiligo with a site in United States, this one is the 3rd largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 3, and was the 55th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Poland
Ages 18–65
CorEvitas · Sites in United States
Ages 12+ · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–99
Elixiron Immunotherapeutics (Hong Kong) Ltd. · Sites in United States, Taiwan
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 14 · Phase 4 1
First in 1995; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 607 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 37 across the 68 interventional studies, 1,750 across the 12 observational. Of the 50 that completed or were terminated, 25 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 80 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Vitiligo — fewer than ten, so there is no comparison to draw.
8 of the studies in Vitiligo with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06163326Phase 3PfizerA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | 2027-03-31 |
| NCT06072183Phase 3PfizerA 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | 2027-07-30 |
| NCT03577327Northwestern UniversityThe Gut and Skin Microbiome in Vitiligo Disease Progression | 2026-12 |
| NCT07223229Elixiron Immunotherapeutics (Hong Kong) Ltd.Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients | 2026-12-31 |
| NCT07108283TakedaA Study of Zasocitinib in Adults With Nonsegmental Vitiligo | 2027-03-26 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Vitiligo with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Study B7981040 is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo (both active and stable vitiligo).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants ≥18 years of age at Screening. Adolescents (12 to \<18 years of age) are also eligible for this study, but only if approved by the local IRB/EC and regulatory health authority. Where these approvals have not been granted, only participants ≥18 years of age will be enrolled.
Disease Characteristics:
Eligible participants must have at both Screening and Baseline:
Active vitiligo is defined as:
Stable vitiligo is defined as an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) are required to have stable disease.
Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.
Other Inclusion Criteria:
Exclusion Criteria:
Any psychiatric condition including recent or active suicidal ideation or behavior that meets any of the following criteria:
Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:
General Infection History:
Specific Viral Infection History:
Medical Conditions, Other:
Prior/Concomitant Therapy:
Have received any of the prohibited treatment regimens specified.
Prior/Concurrent Clinical Study Experience:
Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 [Baseline] or within 5 half-lives, whichever is longer.
Diagnostic Assessments:
Any of the following abnormalities in laboratory values at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:
Screening standard 12-lead that demonstrates clinically relevant abnormalities
Other Exclusion Criteria:
Adolescent participants 12 to \<18 years of age without one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ritlecitinib 50 mg QD (ritilecitinib 50 mg QD arm; approximately 400 participants)
Drug: Ritlecitinib
Placebo (placebo arm; approximately 200 participants)
Drug: Placebo
50 mg capsule
Matching capsule
US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)
Time frame: Week 52
Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)
Time frame: Week 52
Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalities
Safety and tolerability of ritlecitinib in participants with nonsegmental vitiligo
Time frame: Baseline through Week 52
US-Only: Response based on F-VASI75 at 24 and 36 weeks
Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline
Time frame: Weeks 24 and 36
US-Only: Response based on T-VASI50 at 24 and 36 weeks
Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)
Time frame: Weeks 24 and 36
US-Only: Response based on T-VASI75 at 52 weeks
Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)
Time frame: Week 52
US-Only: Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks
Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 24, 36, and 52
US-Only: Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks
Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 24, 36, and 52
US-Only: Patient Global Impression of Severity-Face (PGIS-F)
Proportion of responders based on PGIS-F at 52 weeks
Time frame: Week 52
US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Proportion of responders based on PGIS-V at 52 weeks
Time frame: Week 52
Global (Other than US): Response based on F-VASI75 at 24 and 36 weeks
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)
Time frame: Weeks 24 and 36
Global (Other Than US): Response based on T-VASI50 at 24, 36, and 52 weeks
Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)
Time frame: Weeks 24, 36, and 52
Global (Other than US): Percentage change from baseline (% CFB) in F-VASI at 24, 36, and 52 weeks
Median % CFB in F-VASI in participants treated with ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 24, 36, and 52
Global (Other than US): Percentage change from baseline (% CFB) in T-VASI at 24, 36, and 52 weeks
Median % CFB in T-VASI in participants treated with ritlecitinib 50 mg QD versus placebo
Time frame: Weeks 24, 36, and 52
Global (Other than US): Patient Global Impression of Severity-Face (PGIS-F)
Proportion of responders based on PGIS-F at 24, 36, and 52 weeks
Time frame: Weeks 24, 36, and 52
Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Proportion of responders based on PGIS-V at 24, 36, and 52 weeks
Time frame: Weeks 24, 36, and 52
All Countries: Proportion of participants achieving disease stabilization
The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD compared to placebo
Time frame: Baseline through week 52
Response based on T-VASI50
Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)
Time frame: Baseline through week 4, week 8, week 12, week 48
Response based on F-VASI75
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)
Time frame: Baseline through week 4, week 8, week 12, week 48
Response based on T-VASI75
Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)
Time frame: Baseline through week 4, week 8, week 12, week 24, week 36, week 48
Proportion of participants with sustained improvement in T-VASI
Defined as maintenance of ≥T-VASI50 from Week 36 to Week 52
Time frame: Week 36 through week 52
Proportion of participants with sustained improvement in F-VASI
Defined as maintenance of ≥F-VASI75 from Week 36 to 52
Time frame: Week 36 through week 52
All Countries: Time to rescue medication
Comparing time to rescue medication curves and difference in probabilities of using rescue medication
Time frame: Baseline through week 52
Percentage change from baseline in F-VASI
Median % CFB in F-VASI at appropriate timepoints in participants treated with ritlecitinib 50 mg QD versus placebo
Time frame: Baseline through week 52
Percentage change from baseline in T-VASI
Median % CFB in T-VASI at appropriate timepoints in participants treated with ritlecitinib 50 mg QD versus placebo
Time frame: Baseline through week 52
Response based on T-VASI90
Proportion of participants achieving T-VASI90 (defined as at least 90% improvement in T-VASI from Baseline)
Time frame: Baseline through week 52
Response based on T-VASI100
Proportion of participants achieving T-VASI100 (defined as at least 100% improvement in T-VASI from Baseline)
Time frame: Baseline through week 52
Response based on F-VASI50
Proportion of participants achieving F-VASI50 (defined as at least 50% improvement in F-VASI from Baseline).
Time frame: Baseline through week 52
Response based on F-VASI90
Proportion of participants achieving F-VASI90 (defined as at least 50% improvement in F-VASI from Baseline).
Time frame: Baseline through week 52
Response based on F-VASI100
Proportion of participants achieving F-VASI100 (defined as at least 100% improvement in F-VASI from Baseline).
Time frame: Baseline through week 52
Patient Global Impression of Severity-Face (PGIS-F)
Proportion of responders based on PGIS-F at 24 and 26 weeks
Time frame: Weeks 24 and 36
Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)
Proportion of responders based on PGIS-V at 24 and 36 weeks
Time frame: Weeks 24 and 36
Patient Global Impression of Change-Face (PGIC-F)
To assess the effect of ritlecitinib compared to placebo on the PGIC-F at 24, 36, and 52 weeks
Time frame: Weeks 24, 36, and 52
Patient Global Impression of Change- Overall Vitiligo (PGIC-V)
To assess the effect of ritlecitinib compared to placebo on the PGIC-V at 24, 36, and 52 weeks
Time frame: Weeks 24, 36, and 52
Change from baseline in Dermatology Life Quality Index (DLQI) or Children Dermatology Life Quality Index (CDLQI)
To evaluate the change from baseline in DLQI or CDLQI at week 52
Time frame: Week 52
Change from baseline in the Hospital Anxiety and Depression Scale (HADS)
To assess the effect of ritlecitinib compared to placebo on depression and anxiety subscales of the HADS at week 52
Time frame: Week 52
The proportion of patients achieving absence of depression on HADS depression subscale
Response based on a 'normal' subscale score indicative of an absence of depression (in participants with baseline HADS subscale scores indicative of depression)
Time frame: Week 52
The proportion of patients achieving absence of anxiety on HADS anxiety subscale
Response based on a 'normal' subscale score indicative of an absence of anxiety (in participants with baseline HADS subscale scores indicative of anxiety)
Time frame: Week 52
Showing the first 100 of 115 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2022 to primary completion in Feb 2026, 38 months.
Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600